Chronic stress also plays a role here, disrupting sleep, eating patterns, and metabolic health in ways that medication alone doesn't touch
Clinical Trial Results: What the Data Shows Semaglutide has been evaluated in the STEP (Semaglutide Treatment Effect in People with obesity) trial program, which included four major studies of semaglutide 2.4 mg weekly across different patient populations, including adults with obesity, adults with type 2 diabetes, and adults receiving intensive behavioral support alongside the medication
Data are shown as the mean standard deviation (SD)
Summary: Sulphur burps and diarrhoea are common gastrointestinal side effects of retatrutide, caused primarily by slowed gastric emptying and altered gut motility resulting from its triple receptor agonist activity
Recommendations for blood pressure targets in diabetes range from less than 130/80 mm Hg to less than 140/90 mm Hg
Skin Brightening Support Reduces dark spots & pigmentation